drugset
drugset / Trial / NCT02569541

Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections

NCT02569541 ↗

Phase 2/3 Completed 30 enrolled Arrevus Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.

Timeline

Start
2015-12
Primary completion
2017-10-17
Completion
2019-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium fusidate Unknown 600 mg Oral

Indications

osteomyelitis